Nanoparticle Mediated Oral Delivery of Peptides and Proteins

Peptide and Protein Delivery

Volumn , Issue , 2011, Pages 165-194

  Rekha, M R ^a   Sharma, Chandra P ^a  

^a SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882472488     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-384935-9.10008-2     Document Type: Chapter

References (130)

1. R. Langer (2003) Where a pill won't reach. Scientific American 288 50-57.
2. R. Langer (1998) Drug delivery and targeting. Nature 392 5-10.
3. O.C. Farokhzad and R. Langer (2006) Nanomedicine: Developing smarter therapeutic and diagnostic modalities. Adv. Drug Deliv. Rev. 58 1456-1459.
4. K.A. Janes, P. Calvo and M.J. Alonso (2001) Polysaccharide colloidal particles as delivery systems for macromolecules. Adv. Drug Deliv. Rev. 47 83-97.
5. F. Woodley (1994) Enzymatic barriers for Gl peptide and protein delivery. Crit. Rev. Ther. Drug Carrier Syst. 11 61-95.
6. X.H. Zhou (1994) Overcoming enzymatic and absorption barriers to non-parenterally administered protein and peptide drugs. J. Control. Release 29 239-252.
7. W.S. Snyder, M.J. Cook, E.S. Nassat, L.R. Karhausen, G.P. Howells and I.H. Tipton (1974) International Commission on Radiological Partition 23. Report of the Taskgroup on Reference Man New York: Pergamon Press 139.
8. S. Kerss, A. Allen and A. Garner (1982) A simple method for measuring thickness of the mucus gel layer adherent to rat, frog and human gastric mucosa: Influence of feeding, prostaglandin, N-acetylcysteine and other agents. Clin. Sci. (Lond.) 63 187-195.
9. Y. Aoki, M. Morishita, K. Asai, B. Akikusa, S. Hosoda and K. Takayama (2005) Region-dependent role of the mucous/glycocalyx layers in insulin permeation across rat small intestinal membrane. Pharm. Res. 22 1854-1862.
10. M. Morishita, I. Morishita, K. Takayama, Y. Machida and T. Nagai (1993) Site-dependent effect of aprotinin, sodium caprate, Na2EDTA and sodium glycocholate on intestinal absorption of insulin. Biol. Pharm. Bull. 16 68-72.
11. A. Yamamoto, T. Taniguchi, K. Rikyuu, T. Tsuji, T. Fujita, M. Murakami, et al. (1994) Effect of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm. Res. 11 1496-1500.
12. R.I. Mahato, A.S. Narang, L. Thoma and D.D. Miller (2003) Emerging trends in oral delivery of peptide and proteins. Crit. Rev. Ther. Drug Carr. Syst. 20 153-214.
13. M. Hashimoto, K. Takada, Y. Kiso and S. Muranishi (1989) Synthesis of palmitoyl derivatives of insulin and their biological activities. Pharm. Res. 6 171-176.
14. P. Calceti, S. Salmaso, G. Walker and A. Bernkop-Schnürch (2004) Development and in vivo evaluation of an oral insulin-PEG delivery system. Eur. J. Pharm. Sci. 22 315-323.
15. I. Gomez-Orellana and D.R. Paton (1999) Advances in oral delivery of proteins. Exp. Opin. Ther. Patents 9 247-253.
16. T. Uchiyama, T. Sugiyama, Y.S. Quan, A. Kotani, N. Okada, T. Fujita, et al. (1999) Enhanced permeability of insulin across the rat intestinal membrane by various absorption enhancers: Their intestinal mucosal toxicity and absorption enhancing mechanism of n-lauryl-b-D-maltopyranoside. J. Pharm. Pharmacol. 51 1241-1250.
17. A. Fasano and S. Uzzau (1997) Modulation of intestinal tight junctions by zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. J. Clin. Invest 99 1158-1164.
18. N.N. Salama, N.D. Eddington and A. Fasano (2006) Tight junction modulation and its relationship to drug delivery. Adv. Drug Deliv. Rev. 58 15-28.
19. E.M. Lane, C.M. O'Driscoll and O.I. Corrigan (2005) Quantitative estimation of the effects of bile salts surfactant systems on insulin stability and permeability in the rat intestine using a mass balance model. J. Pharm. Pharmacol. 57 169-175.
20. N.F.H. Ho, J.S. Day, C.L. Barsuhn, P.S. Burton and T.J. Ranb (1990) Biophysical model approaches to mechanistic transepithelial studies of peptides. J. Control. Release 11 3-24.
21. M. Gordberg and I. Gomez-Orellana (2003) Challenge for the oral delivery of macromolecules. Nat. Rev. Drug Discov. 2 289-295.
22. E.S. Swenson and W.J. Curatolo (1992) (C) Means to Enhance Penetration: (2) Intestinal permeability enhancement for proteins, peptides and other polar drugs: Mechanisms and potential toxicity. Adv. Drug Deliv. Rev. 8 39-92.
23. E.S. Swenson, W.B. Milisen and W. Curatolo (1994) Intestinal permeability enhancement: Efficacy, acute local toxicity and reversibility. Pharm. Res. 11 1132-1142.
24. K.D. Hinds and S.W. Kim (2004) Effects of PEG conjugation on insulin properties. Adv. Drug Deliv. Rev. 54 505-530.
25. D. Shah and W.-C. Shen (1996) Transcellular delivery of an insulin-transferrin conjugate in enterocyte-like Caco-2 cells. J. Pharm. Sci. 85 1306-1311.
26. C.Q. Xia, J. Wang and W.-C. Shen (2000) Hypoglycemic effect of insulin-transferrin conjugate in streptozotocin-induced diabetic rats. J. Pharmacol. Exp. Ther. 295 594-600.
27. N.J. Kavimandan, E. Losi, J.J. Wilson, J.S. Brodbelt and N.A. Peppas (2006) Synthesis and characterization of insulin−transferrin conjugates. Bioconjugate Chem. 7 1376-1384.
28. C. Damge, C. Pinto and P. Maincent (2008) Nanoparticle strategies for the oral delivery of insulin. Expert Opin. Drug Deliv. 5 45-68.
29. V.R. Babu, P. Patel, R.C. Mundargi, V. Rangaswamy and T.M. Aminabhavi (2008) Developments in polymeric devices for oral insulin delivery. Expert Opin. Drug Deliv. 5 403-415.
30. C.B. Woitiski, R.A. Carvalho, A.J. Ribiero, R.J. Neufeld and F. Veiga (2008) Strategies toward the improved oral delivery of insulin nanoparticles via gastrointestinal uptake and translocation. BioDrugs 22 223-237.
31. E.-S. Khafagy, M. Morishita, Y. Onuki and K. Takayama (2007) Current challenges in non-invasive insulin delivery systems: A comparative review. Adv. Drug Deliv. Rev. 59 1521-1546.
32. C. Vauthier and K. Bouchemal (2009) Methods for the preparation and manufacture of polymeric nanoparticles. Pharm. Res. 26 1025-1058.
33. P. Couvreur, C. Dubernet and F. Puisieux (1995) Controlled drug delivery with nanoparticles: Current possibilities and future trends. Eur. J. Pharm. Biopharm. 41 2-13.
34. H. Vranckx, M. Demoustier and M. Deleers (1996) A new nanocapsule formulation with hydrophilic core: Application to the oral administration of salmon calcitonin in rats. J. Pharm. Pharmacol. 42 345-347.
35. C. Pinto-Reis, R.J. Neufeld, A.J. Ribeiro and F. Veiga (2006) Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2 8-21.
36. C. Damge, H. Vranckx, P. Balschmidt and P. Couvreur (1997) poly(alkylcyanoacrylate) nanospheres for oral administration of insulin. J. Pharm. Sci. 86 1403-1409.
37. C. Damge, M. Aprahamian, W. Humbert and M. Pinget (2000) Ileal uptake of polyalkylcyanoacrylate nanocapsules in the rat. J. Pharm. Pharmacol. 52 1049-1056.
38. M.S. Meisha, M.B. Sidhom and B. Fasipe (2005) Oral and subcutaneous absorption of insulin poly(alkylcyanoacrylate) nanoparticles. Int. J. Pharm. 288 289-293.
39. S. Sajeesh and C.P. Sharma (2006) Novel pH responsive polymethacrylic acid-chitosan-polyethylene glycol nanoparticles for oral peptide delivery. J. Biomed. Mater. Res. B Appl. Biomater. 76 298-305.
40. A.C. Foss, T. Goto, M. Morishita and N.A. Peppas (2004) Development of acrylic-based copolymers for oral insulin delivery. Eur. J. Pharm. Biopharm. 6 163-169.
41. D.N. Robinson and N.A. Peppas (2002) Preparation and characterization of pH-responsive poly(methacrylic acid-g-poly(ethylene glycol) nanospheres. Macromolecules 35 3668-3674.
42. M. Torres-Lugo and N.A. Peppas (2002) Preparation and characterization of P(MAA-g-EG) nanospheres for protein delivery applications. J. Nanoparticle Res. 4 73-81.
43. E. Mathiowitz, J.S. Jacob, Y.S. Jong, G.P. Carino, D.E. Chickering, D.E. Chaturvedi, et al. (1997) Biologically erodable microspheres as potential oral delivery systems. Nature 386 410-414.
44. S. Furtado, D. Abramson, R. Burrill, G. Olivier, C. Gourd, E. Bubbers, et al. (2008) Oral delivery of insulin loaded poly(fumaric-co-sebacic) anhydride microspheres. Int. J. Pharm. 347 149-155.
45. C.E. Astete and C.M. Sabliov (2006) Synthesis and characterization of PLGA nanoparticles. J. Biomater. Sci. Polymer. 17 247-289.
46. R.C. Mundargi, V.R. Babu, V. Rangaswamy, P. Patel and T.M. Aminabhavi (2008) Nano/micro technologies for delivering macromolecular therapeutics using poly(d, l-lactide-co-glycolide) and its derivatives. J. Control. Release 125 193-209.
47. S. Davaran, Y. Omidi, M.R. Rashidi, M. Anzabi, A. Shayanfar, S. Ghyasvand, et al. (2008) Preparation and in vitro evaluation of linear and star-branched PLGA nanoparticles for insulin delivery. J. Bioactive Comp. Pol. 23 115-131.
48. L. Illum (1998) Chitosan and its use as a pharmaceutical excipient. Pharm. Res. 15 1326-1331.
49. Y. Pan, Y.-J. Li and H.-Y. Zhao (2002) Bioadhesive polysaccharide in protein delivery system: Chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int. J. Pharm. 249 139-147.
50. F. Cui, L. Zhang, J. Zheng and Y. Kawashima (2004) A study of insulin-chitosan complex nanoparticles used for oral administration. STP Pharma. 14 435-439.
51. B. Sarmento, A. Ribeiro and F. Veiga (2007) Oral bioavailability of insulin contained in polysaccharide nanoparticles. Biomacromolecules 8 3054-3060.
52. M.R. Rekha and C.P. Sharma (2009) Synthesis and evaluation of lauryl succinyl chitosan particles towards oral insulin delivery and absorption. J. Control. Release 135 144-151.
53. S.H. Zhao, X.T. Wu, W.C. Guo, Y.M. Du, L. Yu and J. Tang (2010) N-(2-hydroxyl) propyl-3-trimethyl ammonium chitosan chloride nanoparticle as a novel delivery system for Parathyroid Hormone-Related Protein 1-34. Int. J. Pharm. 393 268-272.
54. N. Zhang, J. Li, W. Jiang, C. Ren, J. Li, J. Xin, et al. (2010) Effective protection and controlled release of insulin by cationic β-cyclodextrin polymers from alginate/chitosan nanoparticles. Int. J. Pharm. 393 212-218.
55. N.A. Peppas, J.Z. Hilt, A. Khademhosseini and R. Langer (2006) Hydrogels in biology and medicine: From molecular principles to bionanotechnology. Adv. Mater. 18 1345-1360.
56. D.A. Hutton, J.P. Pearson, A. Allen and S.N.E. Foster (1990) Mucolysis of the colonic mucus barrier by faecal proteinases: Inhibition by interacting polyacrylate. Clin. Sci. (Lond.) 78 265-271.
57. H.L. Lueßen, J.C. Verhoef, G. Borchard, C.-M. Lehr, A.G. de Boer and H.E. Junginger (1995) Mucoadhesive polymers in the peroral peptide drug delivery: II. Carbomer and polycarbophil are potent inhibitors of the intestinal proteolytic enzyme trypsin. Pharm. Res. 12 1293-1298.
58. F. Qian, F. Cui and C. Yin (2006) Preparation, characterization and enzyme inhibition of methylmethacrylate copolymer nanoparticles with different hydrophilic polymeric chains. Eur. Polym. J. 42 1653-1661.
59. A. Bernkop-Schnürch and S.C. Thaler (2000) Polycarbophil–cysteine conjugates as platforms for oral polypeptide delivery systems. J. Pharm. Sci. 89 901-909.
60. A. Bernkop-Schnürch, H. Zarti and G.F. Walker (2001) Thiolation of polycarbophil enhances its inhibition of soluble and intestinal brush border membrane bound aminopeptidase-N. J. Pharm. Sci. 90 1907-1914.
61. G. Borchard, H.L. Lueβen, A.G. de Boer, J.C. Verhoef, C.-M. Lehr and H.E. Junginger (1996) The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: Effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro. J. Control. Release 39 131-138.
62. A.F. Kotzé, H.L. Lueßen, B.J. de Leeuw, A.G. de Boer, J.C. Verhoef and H.E. Junginger (1998) Comparison of the effect of different chitosan salts and N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2). J. Control. Release 51 35-46.
63. P. Artursson, T. Lindmark, S.S. Davis and L. Illum (1994) Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 11 1358-1361.
64. E.K. Anderberg, C. Nystrom and P. Artursson (1992) Epithelial transport of drugs in cell culture. VII. Effects of pharmaceutical surfactant excipients and bile acids on transepithelial permeability in monolayers of human intestinal epithelial (Caco-2) cells. J. Pharm. Sci. 81 879-887.
65. A.M.M. Sadeghi, F.A. Dorkoosh and M.R. Avadi (2008) Permeation enhancer effect of chitosan and chitosan derivatives: Comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells. Eur. J. Pharm. Biopharm. 70 270-278.
66. I. Behrens, A.I. Pena, M.J. Alonso and T. Kissel (2002) Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: The effect of mucus on particle adsorption and transport. Pharm. Res. 19 1185-1193.
67. D.T. O'Hagan (1996) The intestinal uptake of particles and the implications for drug and antigen delivery. J. Anal. 189 477-482.
68. A.T. Florence, A.M. Hillery, N. Hussain and P.U. Jani (1995) Nanoparticles as carriers for oral peptide absorption: Studies on particle uptake and fate. J. Control. Release 36 39-46.
69. A. des Rieux, V. Fievez, M. Garinot, Y.-J. Schneider and V. Préat (2006) Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J. Control. Release 10 1-27.
70. C. Damge, C. Michel, M. Aprahamian and P. Couvreur (1988) New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes 37 246-251.
71. L. Brannon-Peppas (1995) Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery. Int. J. Pharm. 116 1-9.
72. R.A. Jain (2000) The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide) (PLGA) devices. Biomaterials 21 2475-2490.
73. C.P. Reis, R.J. Neufeld, A.J. Ribeiro and F. Veiga (2006) Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine 2 53-65.
74. R. Yang, R. Gao, F. Li, H. He and X. Tang (2011) The influence of lipid characteristics on the formation, in vitro release, and in vivo absorption of protein loaded SLN prepared by the double emulsion process. Drug Dev. Ind. Pharm. 37 139-148.
75. L. Yin, J. Ding, C. He, L. Cui, C. Tang and C. Yin (2009) Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials 30 5691-5700.
76. S. Sakuma, R. Sudo, N. Suzuki, H. Kikuchi, M. Akashi and M. Hayashi (1999) Mucoadhesion of polystyrene nanoparticles having surface hydrophilic polymeric chains in the gastrointestinal tract. Int. J. Pharm. 177 161-172.
77. T. Morçöl, P. Nagappan, L. Nerenbaum, A. Mitchell and S.J.D. Bell (2004) Calcium phosphate-PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin. Int. J. Pharm. 277 91-97.
78. W. Paul and C.P. Sharma (2008) Tricalcium phosphate delayed release formulation for oral delivery of insulin: A proof-of-concept study. J. Pharm. Sci. 97 875-882.
79. R. Ramachandran, W. Paul and C.P. Sharma (2009) Synthesis and characterization of PEGylated calcium phosphate nanoparticles for oral insulin. J. Biomed. Mater. Res. Part B: Appl. Biomater. 88B 41-48.
80. W. Paul and C.P. Sharma (2010) Fatty acid conjugated calcium phosphate nanoparticles for protein delivery. Int. J. Appl. Ceram. Technol. 7 129-138.
81. A. Hashimoto and J. Kawada (1979) Effects of oral administration of positively charged insulin liposomes on alloxan diabetic rats: Preliminary study. Endocrinol. Jpn. 26 337-344.
82. H.M. Patel and B. Ryman (1977) The gastro-intestinal absorption of liposomally entrapped insulin in normal rats. Biochem. Soc. Trans. 5 1054-1055.
83. J.F. Arrieta-Molero, K. Aleck, M.K. Sinha, C.M. Brownscheilde, L.J. Shapiro and M.A. Sperling (1982) Orally administered liposome-entrapped insulin in diabetic animals. A critical assessment. Horm. Res. 16 249-256.
84. C. Weingarten, A. Moufti, J. Delattre, F. Puisieux and P. Couvreur (1985) Protection of insulin from enzymatic degradation by its association to liposomes. Int. J. Pharm. 26 251-257.
85. C. Weingarten, A. Moufti, J.F. Desjeux, T.T. Luong, G. Durand, J.P. Devissaguet, et al. (1981) Oral ingestion of insulin liposomes: Effects of the administration route. Life Sci. 28 2747-2752.
86. K.E. Anderson, B.R. Stevenson and J.A. Rogers (1999) Folic acid-PEO acid-PEO-labeled liposomes to improve gastrointestinal absorption of encapsulated agents. J. Control. Release 60 189-198.
87. M. Garcia-Fuentes, C. Prego, D. Torres and M.J. Alonso (2005) A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly (ethylene glycol) as carriers for oral calcitonin delivery. Eur. J. Pharm. Sci. 25 133-143.
88. K. Yamabe, Y. Kato, H. Onishi and Y. Machida (2003) Potentiality of double liposomes containing salmon calcitonin as an oral dosage form. J. Control. Release 89 429-436.
89. L. Hovgaard, E.J. Mack and S.W. Kim (1992) Insulin stabilization and GI absorption. J. Control. Release 19 99-108.
90. A.M. Hillery (2001) Drug delivery, the basic concepts. A.M. Hillery, A.W. Lloyd, J. Swarbrick (Eds) Drug Delivery and Targeting for Pharmacists and Pharmaceutical Scientists London: Taylor & Francis 1-48.
91. S. Frokjaer and D.E. Otzen (2005) Protein drug stability: A formulation challenge. Nat. Rev. 4 298-306.
92. H.S. Lin, C.-T. Chen, H.-F. Liang, A.R. Kulkarni, P.-W. Lee, C.-H. Chen and H.-W. Sung (2007) Novel nanoparticles for oral insulin delivery via the paracellular pathway. Nanotechnology 18 105102.
93. S. Sajeesh and C.P. Sharma (2006) Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. Int. J. Pharm. 325 147-154.
94. M.A. Karsdal, I. Byrjalsen, M. Azira, M. Arnold, L. Choi, B.J. Rjis, et al. (2009) Influence of food intake on the bioavailability and efficacy of oral calcitonin. Br. J. Clin. Pharmacol. 67 413-420.
95. R.A. Cone (2009) Barrier properties of mucus. Adv. Drug Deliv. Rev. 27 75-85.
96. S.K. Lai, Y.-Y. Wang and J. Hanes (2009) Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 61 158-171.
97. D.J. Thornton and J.K. Sheehan (2004) From mucins to mucus: Toward a more coherent understanding of this essential barrier. Proc. Am. Thorac. Soc. 1 54-61.
98. C. Wickström, J.R. Davies, G.V. Eriksen, E.C.I. Veerman and I. Carlstedt (1998) MUC5B is a major gel-forming, oligomeric mucin from human salivary gland, respiratory tract and endocervix: Identification of glycoforms and C-terminal cleavage. Biochem. J. 334 685-693.
99. H.W. Hovenberg, J.R. Davies and I. Carlstedt (1996) Different mucins are produced by the surface epithelium and the submucosa in human trachea: Identification of MUC5AC as a major mucin from goblet cells. Biochem. J. 318 319-324.
100. J.K. Sheehan and I. Carlstedt (1984) Hydrodynamic properties of human cervical-mucus glycoproteins in 6M-guanidinium chloride. Biochem. J. 217 93-101.
101. D.J. Thornton, D.F. Holmes, J.K. Sheehan and I. Carlstedt (1989) Quantitation of mucus glycoproteins blotted onto nitrocellulose membranes. Anal. Biochem. 182 160-164.
102. P. Gruber, A. Rubinstein, V.H. Li, P. Bass and J.R. Robinson (1987) Gastric emptying of nondigestible solids in the fasted dog. J. Pharm. Sci. 76 117-122.
103. C.-M. Lehr, F.G.J. Poelma, H.E. Junginger and J.J. Tukker (1991) An estimate of turnover time of intestinal mucus gel layer in the rat in situ loop. Int. J. Pharm. 70 235-240.
104. S.A. Galindo-Rodriguez, E. Allemann, H. Fessi and E. Doelker (2005) Polymeric nanoparticles for oral delivery of drugs and vaccines: A critical evaluation of in vivo studies. Crit. Rev. Ther. Drug Carr. Syst. 22 419-464.
105. G. Ponchel and J. Irache (1998) Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv. Drug Deliv. Rev. 34 191-219.
106. A. des Rieux, V. Fievez, M. Garinot, Y.J. Schneider and V. Préat (2006) Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J. Control. Release 116 1-27.
107. H. Takeuchi, H. Yamamoto and Y. Kawashima (2001) Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv. Drug Del. Rev. 23 39-54.
108. F. Atyabi, F.A. Moghaddam, R. Dinarvand, M.J. Zohuriaan-Mehr and G. Ponchel (2008) Thiolated chitosan coated poly hydroxyethyl methacrylate nanoparticles: Synthesis and characterization. Carb. Pol. 74 59-67.
109. A. Bernkop-Schnürch (2005) Thiomers: A new generation of mucoadhesive polymers. Adv. Drug Del. Rev. 57 1569-1582.
110. K. Yoncheva, E. Lizarraga and J.M. Irache (2005) Pegylated nanoparticles based on poly(methyl vinyl ether-co-maleic anhydride): Preparation and evaluation of their bioadhesive properties. Eur. J. Pharm. Sci. 24 411-419.
111. S.K. Lai, D.E. O'Hanlon, S. Harrold, S.T. Man, Y.Y. Wang, R. Cone and J. Hanes (2007) Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl. Acad. Sci. U.S.A. 104 1482-1487.
112. K. Yang, J. Wu and X. Li (2008) Recent advances in research on P-glycoprotein inhibitors. BioScience Trends 2 137-146.
113. J. Iqbal, J. Hombach, B. Matuszczak and A. Bernkop-Schnürch (2010) Design and in vitro evaluation of a novel polymeric P-glycoprotein (P-gp) inhibitor. J. Control. Release 147 62-69.
114. K.B. Chalasani, G.-J. Russell-Jones, S.K. Yandrapu, P.V. Diwan and S.K. Jain (2007) A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. J. Control. Release 117 421-429.
115. K.B. Chalasani, G.-J. Russell-Jones, A.K. Jain, P.V. Diwan and S.K. Jain (2007) Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. J. Control. Release 122 141-150.
116. F. Cui, K. Shi, L. Zhang and Y. Kawashima (2006) Biodegradable nanoparticles loaded with insulin–phospholipid complex for oral delivery: Preparation, in vitro characterization and in vivo evaluation. J. Control. Release 114 242-250.
117. K. Sonaje, Y.-H. Lin and J.-H. Juang (2009) In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 30 2329-2339.
118. C. Damge, P. Maincent and N. Ubrich (2007) Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J. Control. Release 117 271-280.
119. F. Cui, A.-J. Tao, D.-M. Cun, L.Q. Zhang and K. Shi (2006) Preparation of insulin loaded PLGA-Hp55 nanoparticles for oral delivery. J. Pharm. Sci. 96 421-427.
120. K.-H. Song, S.-J. Chung and C.-K. Shim (2005) Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts. J. Control. Release 106 298-308.
121. T. Blunk, D.F. Hochstrasser, J.-C. Sanchez, B.W. Müller and R.H. Müller (1993) Colloidal carriers for intravenous targeting: Plasma protein adsorption patterns on surface modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 14 1382-1387.
122. M. Luck, B.R. Paulke, W. Schröder, T. Blunk and R.H. Müller (1998) Analysis of plasma protein adsorption on polymeric nanoparticles with different surface chacteristics. J. Biomed. Mater. Res. 39 478-485.
123. D.E. Ovens III and N.A. Peppas (2006) Opsonisation, biodistribution and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307 93-102.
124. J.B. Hall, M.A. Dobrovolskaia and A.K. Patri (2007) Characterisation of nanoparticles for therapeutics. Nanomedicine 2 789-803.
125. D. Jacobson-Kram and T. McGovern (2007) Toxicological overview of impurities in pharmaceutical products. Adv. Drug Deliv. Rev. 59 38-42.
126. C.P. Reis, I.V. Figueiredo and R.A. Carvalho (2008) Toxicological assessment of orally delivered nanoparticulate insulin. Nanotoxicology 2 205-217.
127. J.F. Hillyer and R.M. Albrecht (2001) Gastrointestinal persorption and tissue distribution of differently sized colloidal gold nanoparticles. J. Pharm. Sci. 90 1927-1936.
128. N. Hussain, V. Jaitley and A.T. Florence (2001) Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv. Drug Deliv. Rev. 50 107-142.
129. P. Jani, G.W. Halbert, J. Langridge and A.T. Florence (1989) The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J. Pharm. Pharmacol. 41 809-812.
130. P. Jani, G.W. Halbert, J. Langridge and A.T. Florence (1990) Nanoparticle uptake by the rat gastrointestinal mucosa: Quantitation and particle size dependency. J. Pharm. Pharmacol. 42 821-826.